Kornimate/medical-research-clean huggingface dataset:
metformin glycinate in patients with ms or dm2 , hospitalized with covid-19 and sars secondary to sars-cov-2

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2; Metabolic Syndrome; Type 2 Diabetes

Summary: the purpose of this study is to evaluate the efficacy and safety of metformin glycinate at dose of 620 mg twice per day plus standard treatment comparing to standard treatment alone (we will use placebo) of patients who have metabolic syndrome or type 2 diabetes, which have severe acute respiratory syndrome secondary to sars-cov-2.

after being informed about the study and potential risks, all patients will give written informed consent and undergo a 1 day screening period to determine the eligibility for study entry. at day 0, patients who meet the eligibility requirements will be randomized in a double blind (participant and investigator) in a 1:1 ratio to metformin glycinate (620 mg, taken orally twice daily) plus standard treatment or placebo (taken orally,twice daily) plus standard treatment, both will be for 14 days.

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years old 2. ability to understand and the willingness to sign a written informed consent document before any study procedure 3. metabolic syndrome or type 2 diabetes 4. coronavirus infection, severe acute respiratory syndrome sars-cov- 2 confirmed by the polymerase chain reaction test (pcr) ≤ 4 days before of the randomization. 5. hospitalized patient. 6. radiographic evidence of pulmonary infiltrates exclusion criteria: 1. participation in any other clinical trial of an experimental treatment for covid-19 2. evidence of multi-organ failure 3. require mechanical ventilation before randomization 4. pregnant patients

Keywords: sars-cov 2 metabolic syndrome type 2 diabetes severe acute respiratory syndrome metformin glycinate
pregnenolone in the management of schizophrenia patients

Conditions: Schizophrenia

Summary: pregnenolone is a "neurosteroid" and possesses intrinsic behavioral and brain effects in animals, affecting the gaba(a) and other receptors. pregnenolone is serves as the precursor for dehydroepiandrosterone (dhea) and its sulfate ester (dheas). there is evidence of efficacy of dhea augmentation in schizophrenia, we therefore sought to examine the efficacy of augmentation of antipsychotic treatment of schizophrenia patients with pregnenolone. it is hypothesized that the combined effect of antipsychotic agents and pregnenolone would be beneficial in the treatment of negative,depressive, and cognitive symptoms.

either pregnenolone (30 mg/d or 200 mg/d), dhea (400 mg/d)or placebo will be added to regular treatment for 8 weeks. subjects will be assessed at baseline and after 2, 4, 6 and 8 weeks of treatment. an extensive battery of research instruments will be used for assessment of the following domains of interest: psychopathology, insight, side effects, and cognitive functions. plasma pregnenolone, dhea(s), cortisol and other relevant steroids will be assayed at baseline, 2, 4, 6 and 8 weeks of treatment. efficacy and safety of augmentation of antipsychotic treatment with pregnenolone will be analyzed.

Eligibility criteria:
inclusion criteria: * dsm-iv criteria for schizophrenia or schizoaffective disorder * ability and willingness to sign informed consent for participation in the study exclusion criteria: * evidence of organic brain damage, mental retardation, alcohol or drug abuse * prostate nodules or cancer. * moderate symptoms of benign prostatic hypertrophy such as hesitancy, urgency, frequent voiding and feeling of incomplete voiding. * history of ischemic cardiac disease. * renal disease. * hepatic dysfunction. * women with a history of carcinoma of the breast, or any women with a family history of the following: premenopausal breast cancer or bilateral breast cancer in a first degree relative; multiple family members (greater than three relatives) with postmenopausal breast cancer. * women with a history of uterine cancer. * patients with a known hypersensitivity to androgens. * pregnant women.

Keywords: schizophrenia pregnenolone neurosteroids
clinical study to compare various dosing and titration guidelines of insulin delivered via v-go ® in patients with type 2 diabetes initiating basal bolus therapy in primary care offices

Conditions: Diabetes Type II

Summary: the aim of the study is to observe patients with type 2 diabetes on basal insulin alone or basal insulin with oral agents can be efficiently and safely started with meal time insulin using u100 rapid acting insulin analog and v-go® disposable insulin delivery device (v-go) using one of two dose titration algorithms to achieve improved a1c at 4 months.

this study addresses the informational needs of primary care physicians with regard to providing insulin dosing and titration information utilizing a v-go disposable insulin delivery device. we look to compare two treatment arms of insulin dosing and titration in patients with type 2 insulin-dependent diabetes - a fixed dose titration arm, and an arm where 50% of the insulin dose is given at the largest meal of the day. this study will provide practical information on glycemic control, dose requirements and safety in patients with type 2 diabetes on basal insulin with or without oral anti-diabetic agents who are being primarily managed in the primary care office.

Eligibility criteria:
inclusion criteria: patients must meet all of the following inclusion criteria to be eligible for enrollment into the study: * age ≥ 21 and ≤80 at time of study enrollment * ability to read and understand english * bmi ≥ 25 kg/m2 * weight less than or equal to 300 pounds. * a1c ≥8 but ≤12% (most recent value within 4 weeks of baseline visit) * currently using any basal insulin therapy (nph, levemir, lantus) with total daily dose of 30 to 120 units, and where basal dose is greater than the patient's bmi # * willing to attend their physician's office for follow-up visits * willing and able to understand and sign a written informed consent form (icf) indicating that they agree to participate and have been informed of all pertinent aspects of the study * must be willing to take and record at least 3 glucose measurements per time period (pre-breakfast, lunch, dinner and bed) per week. * willing to opt-in into valeritas customer care so that they can receive device support and reminders throughout the study * most recent primary care office visit at one of the participating sites. exclusion criteria:patients presenting with any the following exclusion criteria will not be eligible for enrollment into the study: * patient with confirmed type 1 diabetes and/or patients with a weight greater than 300 lbs. * diagnosis of an autoimmune disease affecting metabolism * currently using glp-1 medications * current (within the last 6 months) or planned use of insulin pump for diabetes management or the use of u500 insulin. * ongoing participation in any clinical study * pregnant, lactating or intending to become pregnant * current chronic systemic steroid use * prior v-go use
us radiomics in advanced cervical cancer

Conditions: Uterine Cervical Neoplasms; Locally Advanced Cervical Cancer; Radiomics; Ultrasound Imaging; Machine Learning; Chemoradiotherapy

Summary: this is a retrospective, multicenter observational study aimed at evaluating the role of ultrasound-based radiomics in patients with locally advanced cervical cancer (lacc). the study will analyze pre-treatment ultrasound images to identify radiomic features that may predict treatment response and disease recurrence. a total of 220 patients treated with exclusive chemoradiotherapy or neoadjuvant chemoradiotherapy followed by radical surgery between 2011 and 2024 will be included. using clinical and imaging data, machine learning models will be developed to distinguish between responders and non-responders, and to identify patients at higher risk of relapse. the goal is to improve personalized care in lacc by integrating radiomic analysis into treatment planning and follow-up strategies.


Eligibility criteria:
inclusion criteria: female patients aged ≥18 years histologically confirmed diagnosis of locally advanced cervical cancer (figo 2018 stage ib3-iva, excluding iia1) histologic subtypes: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma underwent transvaginal or transrectal ultrasound prior to treatment at least one pre-treatment dicom ultrasound image of the primary tumor available treated with either exclusive chemoradiotherapy or neoadjuvant chemoradiotherapy followed by radical surgery completed at least 12 months of follow-up after primary treatment signed informed consent (or equivalent declaration) exclusion criteria: age \<18 years only printed ultrasound images available ultrasound images with poor tumor visualization or with text/markers obscuring the tumor

Keywords: locally advanced cervical cancer cervical cancer uterine cervical neoplasms radiomics ultrasound ultrasound imaging machine learning gynecologic oncology
ibuprofen gel or capsaicin cream for my painful knee osteoarthritis?

Conditions: Osteoarthritis, Knee

Summary: despite evidence that topical non-steroidal anti-inflammatory drugs (nsaids) and capsaicin are effective in osteoarthritis (oa), it is still unclear why they work for some people but not others. the investigators are undertaking an individual patient data (ipd) meta-analysis to identify responders according to patient characteristics, however, no studies report the presence of synovial hypertrophy or neuropathic-like pain. these two traits are of interest as they may be used to optimise the treatment effects of the two drugs which work via different mechanisms to reduce pain in oa. the investigators are therefore conducting this pilot n-of-1 trial series. this pilot n-of-1 trial series will investigate whether a person with oa, who has a different balance between inflammatory and neuropathic pain, shows a preference between these mechanistically different treatments. the trial will also be used to offer recommendations on the use of n-of-1 trial series for individualised (precision) medicine in oa.


Eligibility criteria:
inclusion criteria: * men and non-pregnant women who have had ultrasound and radiographic assessments in the knee pain in the community study o premenopausal women will need to be on an acceptable contraceptive method * aged 40-95 years * knee pain between 4-8 on the nrs * knee osteoarthritis - defined as knee pain plus radiographic changes, based on previous questionnaire responses and radiographic findings * knee pain: individuals with knee pain in and around the knee on most days for at least a month. * radiographic changes: definite joint space narrowing and definite osteophytes (each scoring two or more on the nottingham line drawing atlas) in the tibiofemoral and/or patellofemoral compartments * predominantly neuropathic or inflammatory phenotypes based on previous questionnaire responses (not current status) * predominantly neuropathic phenotype: paindetect questionnaire (pdq) \> 13 and synovial hypertrophy (sh) \<4 mm * predominantly inflammatory phenotype: sh \> 4 mm and pdq \< 13 * if we cannot recruit enough people with the above thresholds, we will base recruitment on the overall distribution of pdq and sh scores from the population. the third tertile of pdq and the first tertile of sh for neuropathic and the first tertile of pdq and the third tertile of sh for inflammatory phenotypes. exclusion criteria: * inability to give informed consent * daily use of oral nsaids for the last two weeks * prior use of ibuprofen gel or zacin on the affected knee(s) * terminal or untreated major mental illness * pregnancy or breastfeeding * hypersensitivity or allergy to topical nsaids, capsaicin, or other ingredients in the preparations. this includes individuals that experience attacks of asthma, urticaria, or acute rhinitis that are precipitated by nsaids * current treatment for stomach or duodenal ulcers * total joint replacement of affected joint * renal failure * taking anticoagulants

Keywords: osteoarthritis n-of-1 ibuprofen capsaicin nsaid topical
a multicenter, open-label randomized crossover trial to assess subject preference for kemstro™ compared to conventional baclofen tablets in subjects with stable multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this was a multicenter, open-label, randomized, crossover trial in subjects with ms who were already taking a stable dose of baclofen (up to 80 mg/day) for spasticity. the trial was designed to assess subject preference for kemstro or conventional baclofen. at visit 1, subjects were screened, and if qualified, were randomly assigned to one of two following treatment sequences: kemstro/conventional baclofen or conventional baclofen/kemstro.


Eligibility criteria:
inclusion criteria: * stable dose of baclofen exclusion criteria: * not stable dosing
the prevalence of obesity for schizophrenia inpatients in taiwan

Conditions: Schizophrenia; Obesity

Summary: this study is the first hospital-based, cross-sectional study to discuss the prevalence of obesity among 710 inpatients with schizophrenia.


Eligibility criteria:
inclusion criteria: 1. diagnosis as icd 295 2. living in rehabilitation ward during 2010/03/22\~2010/04/02 exclusion criteria: none

Keywords: schizophrenia inpatient obesity prevalence
stress reduction in ovarian cancer

Conditions: Ovarian, Fallopian, and Primary Peritoneal Cancer

Summary: the purpose of this study is to investigate the effects of a stress reduction program on the quality of life of ovarian cancer patients during primary adjuvant chemotherapy.


Eligibility criteria:
inclusion criteria: * subjects must have an initial diagnosis of ovarian, fallopian tube or primary peritoneal cancer who completed primary ovarian cancer surgery or 3 cycles of neoadjuvant chemotherapy with interval cytoreductive surgery (ics). * final pathology diagnosis of stage i-iv ovarian, fallopian tube or primary peritoneal cancer with plan to receive primary adjuvant chemotherapy or completion of chemotherapy after ics. * receive chemotherapy at the university of wisconsin-madison. * subjects must be at least 18 years of age. * english-speaking * subjects must be able to use audio media, and read and understand the study manual. * ecog performance status 0-2. * subjects must have a phone. exclusion criteria: * subjects participating in a meditation practice more than 1 hour per week prior to surgery and/or chemotherapy administration. * subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer. * subjects with diagnosis of chronic fatigue syndrome (cfs). * subjects unable to use audio media due to auditory dysfunction. * subjects unable to read written english. * subjects who are prisoners or incarcerated.
determinants of muscle strength in chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: aim of this study is to determine in chronic kidney disease patients: * the involvement of malnutrition inflammation and atherogenesis syndrome (increase in c reactive protein and decrease in serum albumin) on voluntary muscle strength impairment * the relationship between voluntary muscle strength and muscle mass * the relationship between voluntary muscle strength and lean body mass * the correlation between voluntary muscle strength and physical activity

aim of this study is to determine in chronic kidney disease patients: * the involvement of malnutrition inflammation and atherogenesis syndrome (increase in c reactive protein and decrease in serum albumin) on voluntary muscle strength impairment (estimated by handheld dynamometer) * the relationship between voluntary muscle strength and muscle mass (estimated by creatinine index) * the relationship between voluntary muscle strength and lean body mass (estimated by bioelectrical impedance analysis) * the correlation between voluntary muscle strength and physical activity (the physical activity being estimated by the "voorrips" score questionnaire)

Eligibility criteria:
inclusion criteria: * chronic kidney disease patient with extrarenal replacement therapy by hemodialysis for at least 3 months * stable clinical condition (absence of infection, stroke or acute decompensation) exclusion criteria: * chronic kidney disease without extrarenal replacement therapy * history of renal transplantation

Keywords: chronic kidney disease malnutrition inflammation atherogenesis syndrome muscle strength muscle mass lean body mass physical activity
a study of strontium90 beta radiation with lucentis to treat age-related macular degeneration

Conditions: Macular Degeneration

Summary: the objective of the cabernet trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (cnv) associated with wet age-related macular degeneration (amd). the epi-rad90™ ophthalmic system treats neovascularization of retinal tissue by means of a focal, directional delivery of radiation to the target tissues in the retina. using standard vitreoretinal surgical techniques, the sealed radiation source is placed temporarily over the retinal lesion by means of a handheld medical device.

therapeutic advances in the arena of neovascular age-related macular degeneration (amd) have provided multiple treatment options for the disease. radiotherapy has been studied in multiple clinical trials in the past with many studies showing a therapeutic benefit. treatment with radiotherapy and anti-vegf compounds is a promising approach to treating amd.

Eligibility criteria:
inclusion criteria: * subjects must have predominantly classic, minimally classic, or occult with no classic lesions, as determined by the investigator, secondary to amd, with a total lesion size (including blood, scarring, and neovascularization) of \< 12 total disc areas (21.24 mm2), and a gld ≤5.4 mm * subjects must be age 50 or older exclusion criteria: * subjects with prior or concurrent subfoveal cnv therapy including thermal laser photocoagulation (with or without photographic evidence), photodynamic therapy, injections with macugen®, intravitreal or subretinal steroids, transpupillary thermotherapy (ttt), and systemic anti-angiogenic or intravitreal anti-angiogenic agents in study eye. (note: this includes subjects with no known history, but with photographic evidence of prior therapy) * subjects who underwent previous radiation therapy to the eye, head or neck * subjects that have been previously diagnosed or have retinal findings consistent with type 1 or type 2 diabetes mellitus

Keywords: macular degeneration amd wet age-related macular degeneration
prevalence of antibodies against sars-cov-2 virus that causes covid-19 in tübingen children

Conditions: Severe Acute Respiratory Syndrome

Summary: this is a prospective, longitudinal study to determine the incidence of sars-cov-2 infection in children and adolescents by measuring specific antibodies in non-invasive saliva sampled in kindergartens and schools in a defined city area. the study includes an additional arm to validate the elisa for anti-sars-cov-2 reactive antibody measurements in saliva compared against blood collected in adult volunteers in a bimonthly follow-up period for 12 months.

the world is confronting coronavirus disease-2019 (covid-19) pandemic caused by sars-cov-2 virus, which is causing many deaths and burden on intensive care facilities. data regarding epidemiologic characteristics in children and young adults is limited, especially in the context of educational settings. due to mild symptoms or even asymptomatic cases in children, the rate of sars-cov-2 infected children is underestimated. therefore, the present study aims to determine the incidence of sars-cov-2 infection in children at 3 timepoints during 12 months expressed as seroconversion measured in non-invasive saliva sampling in tübingen, a defined study area. children and adolescents (n = 1850) in the age of 1 to 17 years will be recruited via child-care, kindergarten and primary and secondary schools and followed-up for 12 months: shortly after release of lock-down measures in summer 2020, before winter and after the winter. an adult cohort (adult comparator group) is sampled at the same time points for incidence comparisons. to validate the elisa for sars-cov-2 antibody measurements in saliva compared to blood, and to understand the half-life of sars-cov-2 antibodies in respective body fluids, peripheral blood and in saliva will be sampled every 2 months in an additional adult group (adult validation group).

Eligibility criteria:
inclusion criteria: * children from 1 months to 18 years * written informed consent of the parent/legal guardian (study population is minor) * written assent when children are ≥ 12 years * enrolled in a kita, kindergarden, primary, or secondary school located in tübingen adult population: * individuals \>18 years who recovered from a confirmed sars-cov-2 infection. * or individuals \> 18 years with an unknown status of previous sars-cov-2 infection exclusion criteria: * unwilling to give consent

Keywords: sars-cov-2 antibodies saliva children epidemiology
effect of meal replacement beverage(glucerna) on body composition,lipid metabolism and blood pressure

Conditions: Obesity

Summary: effect of meal replacement beverage(glucerna) on body composition,lipid metabolism and blood pressure

the effect of meal replacement beverage(glucerna) on body composition,lipid metabolism and blood pressure in patients with obesity

Eligibility criteria:
inclusion criteria: 1. age：14\~60years 2. bmi ≥ 28kg/m2 3. without liver, kidney, gastrointestinal and other major organic serious diseases,lactating women, pregnancy
efficacy of phosphate binding in healthy volunteers: chewed versus crushed lanthanum carbonate

Conditions: Hyperphosphatemia in Chronic Kidney Disease

Summary: patients with end-stage renal disease (esrd) commonly have high concentrations of phosphorous, a mineral, in the blood (hyperphosphatemia). this is a result of their inability to excrete phosphorous by the kidneys. this in turn may result in the development of a condition known as secondary hyperparathyroidism and renal osteodystrophy or bone disease. as such, these patients often receive medications known as phosphate binders such as calcium carbonate or acetate, sevelamer, aluminum hydroxide and lanthanum carbonate to manage and treat hyperphosphatemia. lanthanum carbonate is a newly available phosphate binding agent that is effective in the management of hyperphosphatemia and preventing secondary hyperparathyroidism. it works in the gastrointestinal tract by binding to the phosphorus in the diet. esrd patients taking lanthanum carbonate are counseled to chew the tablets completely before swallowing, with or immediately after meals. however, patients who are intubated or receiving nutrition via feeding tubes are unable to chew the tablets. for these patients, medications are commonly crushed and administered via the tube. moreover, some patients prefer to crush the tablets and mix it with food instead of chewing. to date, it is not known if crushing the lanthanum carbonate tablets prior to administration and taking it with food would be as effective as chewing them. the purpose of this study is to compare the efficacy of phosphate binding between chewed and crushed lanthanum carbonate tablets.


Eligibility criteria:
inclusion criteria: * men and women at least 18 years of age * no clinically significant abnormal findings on clinical laboratory evaluation and medical history * within 15% of ideal body weight for height and build according to the metropolitan life tables5 * women of child-bearing potential (premenopausal and not surgically sterilized) who have a negative pregnancy test * women who are sexually active must be using effective means of contraception exclusion criteria: * history of dysphagia or swallowing disorders * clinically significant illness within 3 months of study enrollment * concomitant use of medication that might interact with lanthanum carbonate * pregnant or intends to become pregnant within 30 days of completing the study * breast feeding * alcohol or controlled substance abuse * use of an investigational agent within 30 days of study entry